IP-10 as a Non Sputum Biomarker in TB Treatment Monitoring

Yuhpita Indah Efriyani, Ida Parwati, Nina Tristina, Anna Tjandrawati

Abstract


There are currently still limitations in the diagnosis of tuberculosis (TB). Sputum collection as specimen for diagnosis is not only difficult but also has low sensitivity.In blood, IP-10/CXCL-10 chemokine plays a role in inducing the movements of chemotactic inflammatory cells towards the sites of inflammation. A high level of IP-10 is found in active pulmonary TB patients and significantly decline after the patients have completed the TB treatments. The aim of this study was to analyze the decline of the IP-10 level before and after 2 months of TB treatment. This study was conducted from March­ toJuni 2020. This was a comparative observational cohort study on active pulmonary TB patients who were >18 years old at the DOTS Clinic of Dr. Hasan Sadikin General Hospital Bandung. Thirty patients who met the inclusion criteria were followed up until 2 months of TB treatment. Serum of  these patients were collected and examined for the IP-10 level before and after 2 months of TB treatment. It was demonstrated that the median IP-10 level in new active pulmonary TB patients was 384.1 pg/mL (136.70–779.80) and dropped to 251.85 pg/mL (91.10–698.30) (p<0l001) two months of TB treatment. Thus, the IP-10 level in the active pulmonary TB patients is significantly declined (p<0.001) after 2 months of TB treatment and that serum IP-10 level could be considered as a non-sputum-based marker to monitor TB treatment.

Keywords


IP-10, Tuberculosis, Tuberculosis treatment monitoring.

Full Text:

PDF

References


WHO. Global tuberculosis report 2020. France: WHO; 2020.

Santos VS, Goletti D, Kontogianni K, Adams ER, Molina-Moya B, Dominguez J, et al. Acute phase proteins and IP-10 as triage tests for the diagnosis of tuberculosis: systematic review and meta-analysis. Clin Microbiol Infect. 2019;25(2):169–77.

Goletti D, Lee R, Wang J-Y, Walter N, Ottenhoff T. Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease. Respirology. 2018;23(5):455–66.

García-Basteiro AL, Mambuque E, den Hertog A, Saavedra B, Cuamba I, Oliveras L, et al. IP-10 kinetics in the first week of therapy are strongly associated with bacteriological confirmation of tuberculosis diagnosis in hiv-infected patients. Sci Rep. 2017;7(1):14302.

Goletti D, Petruccioli E, Joosten SA, Ottenhoff THM. Tuberculosis biomarkers: from diagnosis to protection. Infect Dis Rep. 2016;8(2):6568.

Tonby K, Ruhwald M, Kvale D, Dyrhol-Riise A. IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection. Sci Rep. 2015;5:9223.

Wergeland I, Pullar N, Assmus J, Ueland T, Tonby K, Feruglio S, et al. IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy. J Infect. 2015;70(4):381–91.

Villar-Hernández R, Latorre I, De Souza-Galvão ML, Jiménez MA, Ruiz-Manzano J, Pilarte J, et al. Use of IP-10 detection in dried plasma spots for latent tuberculosis infection diagnosis in contacts via mail. Sci Rep. 2019;9(1):3943.

Novel N. Chegou, Jan Heyckendorf, Gerhard Walzl, Christoph Lange, Ruhwald M. Beyond the IFN-c horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis. Eur Respir J. 2013;43(5):1472–86.

Hong JY, Jung GS, Kim H, Kim YM, Lee HJ, Cho S-N, et al. Efficacy of inducible protein 10 as a biomarker for the diagnosis of tuberculosis. Int J Infect Dis. 2012;16(12):e855-9.

Ruhwald M, Aabye MG, Ravn P. IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions. Expert Rev Mol Diagn. 2012;12(2):175–87.

Kim SY, Kim J, Kim DR, Kang YA, Bong S, Lee J, et al. Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis. BMC Infect Dis. 2018;18(1):240.

USAID. International Standards for Tuberculosis Care TB care I. 3rd ed. San Fransisco: United States Agency for International Development (USAID); 2014.

World Health Organization. MDR-TB Indonesia Update 2016. Indonesia: WHO; 2019. p. 1–2.

Elabscience. Human IP-10/CXCL10(Interferon Gamma Induced Protein 10kDa) ELISA Kit. Elabscience Biotechnology Inc. 7th ed. Texas: Elabscience; 2017;. Available from: https://www.elabscience.com/p-human_ip_10_cxcl10_interferon_gamma_induced_protein_10kda_elisa_kit-17914.html.

El-emiry FA, Attia GA, Ahmad AY, Sakr BM. Diagnostic value of inducible protein-10 in pulmonary tuberculosis. Egyptian J Chest Dis Tuberculosis. 2016;65(1):219–25.

Mihret A, Bekele Y, Bobosha K, Kidd M, Aseffa A, Howe R, et al. Plasma cytokines and chemokines differentiate between active disease and non-active tuberculosis infection. J Infect. 2013;66(4):357–65.

Hoel IM, Jørstad MD, Marijani M, Ruhwald M, Mustafa T, Dyrhol-Riise AM. IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting. Sci Rep. 2019;9(1):3871.




DOI: https://doi.org/10.15395/mkb.v53n1.2161

Article Metrics

Abstract view : 628 times
PDF - 449 times

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


 


Creative Commons License
MKB is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

 


View My Stats